temozolomide — CareFirst (Caremark)
Soft tissue sarcoma (STS)
Initial criteria
- Authorization may be granted for treatment of STS.
Reauthorization criteria
- Authorization may be renewed if there is no evidence of unacceptable toxicity or disease progression while on the current regimen.
Approval duration
12 months